TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10231910

Group type: EXPERIMENTAL
Intervention: Flexor digitorum accessorius longus (FDAL) presence in asymptomatic individuals
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flexor digitorum accessorius longus (FDAL) appearance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flexor digitorum accessorius longus (FDAL) differentiation
Number of subjects: 100
Study: 8665038

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation counseling and metered-dose inhaler containing ipratropium bromide (two inhalations three times daily)
Number of subjects: 5733

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 5733
Study: 1852339

Group type: EXPERIMENTAL
Intervention: Detailed discussion on CPR (intervention group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no detailed discussion on CPR)
Number of subjects: 100
Study: 6668225

Group type: EXPERIMENTAL
Intervention: 3 g of ascorbate daily
Number of subjects: 2

Group type: COMPARATOR
Intervention: Low intake of ascorbate
Number of subjects: 2
Study: 30365922

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200-3000 mg/d)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 29766596

Group type: EXPERIMENTAL
Intervention: Commercially available mobile app-delivered mindfulness training (AMT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waitlist control (WC)
Number of subjects: 112
Study: 26708714

Group type: EXPERIMENTAL
Intervention: MIYCN-Intervention
Number of subjects: 5824

Group type: COMPARATOR
Intervention: MIYCN-Control
Number of subjects: 5824

Group type: COMPARATOR
Intervention: Comparison
Number of subjects: 5824

Group type: COMPARATOR
Intervention: Pre-intervention
Number of subjects: 5824
Study: 25123352

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (0.9% diflurosilane) biannually
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo applications
Number of subjects: 328
Study: 22526415

Group type: EXPERIMENTAL
Intervention: Plastic wound ring drapes (RD)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group without RD
Number of subjects: 109
Study: 20026572

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Walking outdoors
Number of subjects: 39
Study: 16752587

Group type: EXPERIMENTAL
Intervention: Full attention during study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided attention during study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast recognition judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow recognition judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study-test congruence (picture size or speaker's voice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full attention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divided attention
Number of subjects: 0
Study: 14992000

Group type: EXPERIMENTAL
Intervention: 20 mg of sibutramine hydrochloride capsule
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference sibutramine capsules
Number of subjects: 20
Study: 10882858

Group type: EXPERIMENTAL
Intervention: Diflouromethlyornithine (DFMO)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 116
Study: 8742097

Group type: EXPERIMENTAL
Intervention: G‐CSF 5 mu g/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: G‐CSF 8 mu g/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: G‐CSF 10 mu g/kg
Number of subjects: 45
Study: 1524742

Group type: EXPERIMENTAL
Intervention: Zinc-containing alloys
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-zinc alloys
Number of subjects: 39
Study: 3893778

Group type: EXPERIMENTAL
Intervention: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 1 tablet
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 2 tablets
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine per tablet) - 3 tablets
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fansimef (all doses)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fansimef (3 tablets)
Number of subjects: 150
Study: 30419096

Group type: EXPERIMENTAL
Intervention: Exercise intervention (individualized moderate-intensity resistance, balance, and walking exercises, 2 daily sessions)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 370

Group type: COMPARATOR
Intervention: Usual-care group (control)
Number of subjects: 370
Study: 30012641

Group type: EXPERIMENTAL
Intervention: Plasma proenkephalin A 119‐159 (penKid)
Number of subjects: 956
Study: 25919484

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23117168

Group type: EXPERIMENTAL
Intervention: Adult non-cultivated bone marrow stem cells (group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No intervention (group B)
Number of subjects: 43
Study: 22233789

Group type: EXPERIMENTAL
Intervention: Dry-land strength training program (S)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electrical stimulation training program (ES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 24
Study: 20012122

Group type: EXPERIMENTAL
Intervention: High quality RCTs classified using the original cut off of the PEDro scale (cut off of 6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High quality RCTs classified using the modified cut off of the PEDro scale (cut off of 5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Linear regression analysis between year of publication and quality rate
Number of subjects: 18
Study: 18576903

Group type: EXPERIMENTAL
Intervention: Dicloxacillin 500 mg alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dicloxacillin 500 mg plus probenecid 1 g
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dicloxacillin 500 mg plus cyclosporine 5 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ABCB1 exon 26 TT polymorphism
Number of subjects: 22
Study: 15765455

Group type: EXPERIMENTAL
Intervention: 2 mg morphine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 1 mg morphine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 81
Study: 12455724

Group type: EXPERIMENTAL
Intervention: Antioxidant treatment with glutathione (1200 mg i.v. at the end of each dialysis session) and a vitamin E-bonded HD membrane (CL-E)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Antioxidant treatment
Number of subjects: 38
Study: 20670489

Group type: EXPERIMENTAL
Intervention: Percutaneous automated lumbar nucleotomy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Traditional macro-procedure discectomy
Number of subjects: 158
Study: 7854225

Group type: EXPERIMENTAL
Intervention: Emergency contraception knowledge among rural GPs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Emergency contraception knowledge among urban GPs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Frequency of prescribing emergency contraception by urban GPs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Frequency of prescribing emergency contraception by rural GPs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Female GPs prescribing emergency contraception
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Male GPs prescribing emergency contraception
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Provision of information about emergency contraception by urban GPs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Provision of information about emergency contraception by rural GPs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Inclusion of emergency contraception information in contraceptive discussions
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Provision of information only if requested by women
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: GPs providing information as a back-up to barrier methods
Number of subjects: 160
Study: 1936472

Group type: EXPERIMENTAL
Intervention: Combination therapy (metformin + glibenclamide), n = 60
Number of subjects: 116

Group type: COMPARATOR
Intervention: Metformin monotherapy, n = 28
Number of subjects: 116

Group type: COMPARATOR
Intervention: Glibenclamide monotherapy, n = 28
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Obese patients, n = 69
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Non-obese patients, n = 47
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HDL-cholesterol
Number of subjects: 116
Study: 7252648

Group type: EXPERIMENTAL
Intervention: Energy intake (lipid) at 50 to 80 nonprotein kcal/kg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrogen intake at 494 to 655 mg/kg/day with constant low energy intake (mean = 53 kcal/kg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrogen intake at higher energy intakes (mean = 81 kcal/kg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Energy intake greater than 70 kcal/kg/day with nitrogen infusion of 430 to 560 mg/kg/day (2.7 to 3.5 gm protein/kg/day)
Number of subjects: 22
Study: 31532136

Group type: EXPERIMENTAL
Intervention: Tongyuan acupuncture
Number of subjects: 74

Group type: COMPARATOR
Intervention: Scalp acupuncture
Number of subjects: 74
Study: 28755104

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (84 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral mirtazapine (30 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24404992

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural anger management intervention
Number of subjects: 129

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 129
Study: 24089418

Group type: EXPERIMENTAL
Intervention: Ferritin in postmenopausal women
Number of subjects: 3932

Group type: EXPERIMENTAL
Intervention: Ferritin in premenopausal women aged ≥ 46 y
Number of subjects: 3932

Group type: COMPARATOR
Intervention: Hemoglobin
Number of subjects: 3932
Study: 21298294

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mg combined with fentanyl 25 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 7.5 mg combined with fentanyl 15 μg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mg combined with fentanyl 10 μg
Number of subjects: 120
Study: 19704396

Group type: EXPERIMENTAL
Intervention: Encouragement from at least 1 network member to use male condom
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Encouragement from at least 1 network member to use female condom
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Dense female condom conversation networks (at least 2 network members know one another)
Number of subjects: 157
Study: 17235610

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Citalopram 20 mg/day
Number of subjects: 15
Study: 16137055

Group type: EXPERIMENTAL
Intervention: 5-day rabeprazole-based triple therapy (rabeprazole 10 mg twice daily, clarithromycin 500 mg twice daily, furazolidone 100 mg twice daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: 7-day triple standard therapy (rabeprazole 10 mg twice daily, clarithromycin 500 mg twice daily, furazolidone 100 mg twice daily)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 5-day rabeprazole-based triple therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: 7-day triple standard therapy
Number of subjects: 95
Study: 10899240

Group type: EXPERIMENTAL
Intervention: Formoterol 24, 48, 96 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol 100, 200, 400 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9401929

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (Froben) 50 mg, 3 times per day for 30 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo drug
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Surgically treated sites (both Flurbiprofen and placebo)
Number of subjects: 19
Study: 8419023

Group type: EXPERIMENTAL
Intervention: t-PA (0.8 mg/kg i.v.; maximum, 80 mg) plus conventional antianginal therapy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo plus conventional antianginal therapy
Number of subjects: 306
Study: 3530602

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 58

Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 58
Study: 31820599

Group type: EXPERIMENTAL
Intervention: Jingu three-needle therapy combined with Xingnao Kaiqiao acupuncture
Number of subjects: 96

Group type: COMPARATOR
Intervention: Xingnao Kaiqiao acupuncture (control group)
Number of subjects: 96
Study: 29505863

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil (5‐FU) 5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 0
Study: 27553623

Group type: EXPERIMENTAL
Intervention: Active laser treatment (PBMT with 904-nm GaAs diode laser, 30 mW average power, 25 Hz pulse frequency, 3.6 J/cm2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham (placebo) treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active laser treatment (PBMT)
Number of subjects: 30
Study: 24920270

Group type: EXPERIMENTAL
Intervention: Chlorella (5 g/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 22579072

Group type: EXPERIMENTAL
Intervention: Tai Chi (24 forms simplified Tai Chi)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Stretching and toning exercise
Number of subjects: 389
Study: 20455694

Group type: EXPERIMENTAL
Intervention: L. fermentum CECT5716 (Group A)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: L. salivarius CECT5713 (Group B)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Antibiotic therapy (Group C)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Probiotic groups (A and B)
Number of subjects: 352
Study: 19017589

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy plus cognitive behavior therapy
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study: 16097043

Group type: EXPERIMENTAL
Intervention: Metoclopramide (Met)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no Met)
Number of subjects: 32
Study: 15458100

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) technology used in developed virtual environments (VE) for the treatment of eating disorders.
Number of subjects: 0
Study: 12135314

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amlodipine (calcium antagonist)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vitamin C infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: L-NMMA (nitric oxide synthase inhibitor)
Number of subjects: 18
Study: 9649005

Group type: EXPERIMENTAL
Intervention: Background music and conversation related to the patient's complaints (n=50)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Background music and conversation unrelated to the patient (n=53)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Background music only, with staff maintaining silence (n=49)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Complete silence (n=47)
Number of subjects: 221
Study: 7517409

Group type: EXPERIMENTAL
Intervention: Zatosetron (100 micrograms/kg) in dogs
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zatosetron (50 mg) in men
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo in men
Number of subjects: 28
Study: 2638185

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2% copolymer)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 118
Study: 4947492

Group type: EXPERIMENTAL
Intervention: Standard daily continuation chemotherapy with isoniazid plus PAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fully supervised treatment with streptomycin and high dosage isoniazid, given twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 months sanatorium treatment
Number of subjects: 0
Study: 31648149

Group type: EXPERIMENTAL
Intervention: GPiam‐DBS ON
Number of subjects: 11

Group type: COMPARATOR
Intervention: GPiam‐DBS OFF
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GPiam‐DBS
Number of subjects: 11
Study: 25969966

Group type: EXPERIMENTAL
Intervention: 6-week balance training program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 70
Study: 23077972

Group type: EXPERIMENTAL
Intervention: 48-hour ABPM with BP measured at 20-min intervals during the day and 30-min intervals at night.
Number of subjects: 3344

Group type: COMPARATOR
Intervention: 24-hour ABPM with BP measured at the same intervals as above.
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: ABPM profiles modified to simulate a sampling rate of one BP measurement every 1 or 2 hours for 48 hours.
Number of subjects: 3344

Group type: COMPARATOR
Intervention: ABPM for only 24 hours.
Number of subjects: 3344
Study: 22145912

Group type: EXPERIMENTAL
Intervention: ProMo intervention (includes Standard Care and a year-long program with evaluation/modification of environmental hazards, guidance for safe walking, pain management, progressive home exercise program, and physical activity counseling)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard Care (written home exercise program with 5-7 exercises for lower limbs)
Number of subjects: 81
Study: 19891770

Group type: EXPERIMENTAL
Intervention: Low-dose adenosine infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 17257450

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) trough levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) without therapeutic drug monitoring (TDM)
Number of subjects: 0
Study: 12771969

Group type: EXPERIMENTAL
Intervention: 20 g spread enriched with 1.6 g plant sterols as fatty acid esters
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control spread
Number of subjects: 185
Study: 11025373

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy only
Number of subjects: 158

Group type: COMPARATOR
Intervention: Postoperative hormonal treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 158
Study: 9334909

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7943921

Group type: EXPERIMENTAL
Intervention: Intravenous induction with sodium thiopental and muscle relaxants (succinylcholine chloride or alcuronium chloride)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Awake intubation under intravenous sedation with diazepam and topical anesthesia with 4% lidocaine
Number of subjects: 20
Study: 31994366

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selepressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitric oxide synthase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylene blue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study: 30706575

Group type: EXPERIMENTAL
Intervention: BIS-guided fluid management
Number of subjects: 201

Group type: COMPARATOR
Intervention: Clinical method-guided management (Control)
Number of subjects: 201
Study: 30688281

Group type: EXPERIMENTAL
Intervention: Delayed primary closure (DPC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 34
Study: 26137575

Group type: EXPERIMENTAL
Intervention: Single-dose R-bambuterol (2.5 mg, 5 mg, or 10 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Multiple-dose R-bambuterol (5 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single-dose rac-bambuterol (10 mg)
Number of subjects: 48
Study: 24277856

Group type: EXPERIMENTAL
Intervention: Intranasal OXT treatment (24 IU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22019033

Group type: EXPERIMENTAL
Intervention: Animated biofeedback along with pelvic floor muscle exercises and behavioral modification
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative therapy (behavioral modification only)
Number of subjects: 80
Study: 19475640

Group type: EXPERIMENTAL
Intervention: High adiponectin concentrations
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: High adiponectin concentrations among moderately/very active men
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: High adiponectin concentrations among sedentary/minimally active men
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: C-peptide and leptin
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations
Number of subjects: 1407
Study: 16767844

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day) and E (100 mg/day) supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study: 14709123

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion (1000 mg in 300 mL normal saline)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion (1000 mg in 300 mL normal saline) + Chlorpheniramine bolus (10 mg IV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 11504985

Group type: EXPERIMENTAL
Intervention: Perinatally HIV‐1‐infected children
Number of subjects: 212
Study: 9597289

Group type: EXPERIMENTAL
Intervention: Manipulation under local anaesthetic
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: External splintage with Plaster of Paris (POP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No external splintage (none-POP)
Number of subjects: 33
Study: 8161320

Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide (PB) 90 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3283384

Group type: EXPERIMENTAL
Intervention: Ibuprofen (prophylactic course, dosage not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 0